A prospective open-label study of aripiprazole in fragile X syndrome

Psychopharmacology

Volumn 216, Issue 1, 2011, Pages 85-90

  Erickson, Craig A ^a,b,c   Stigler, Kimberly A ^a,b,c   Wink, Logan K ^a,b,c   Mullett, Jennifer E ^a,b,c   Kohn, Arlene ^a,b,c   Posey, David J ^a,b,c   McDougle, Christopher J ^a,b,c  

^a INDIANA UNIVERSITY   (United States)

^b Christian Sarkine Autism Treatment Center   (United States)

^c RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

Aripiprazole; Fragile X syndrome; Irritability

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ABERRANT BEHAVIOR CHECKLIST IRRITABILITY SCALE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AKATHISIA; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENURESIS; FATIGUE; FEMALE; FRAGILE X SYNDROME; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; MALE; NAUSEA AND VOMITING; NEUROPSYCHOLOGICAL TEST; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SLURRED SPEECH; WEIGHT CHANGE;

ADOLESCENT; ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; CHILD; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; PILOT PROJECTS; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHOLOGICAL TESTS; QUINOLONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959922922     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2194-7     Document Type: Article

References (27)

1. MG Aman NN Singh AW Stewart CJ Field 1985 The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects Am J Ment Defic 5 485 491 (Pubitemid 15104762)
2. R Amaria L Billeisen R Hagerman 2001 Medication use in fragile X syndrome Mental Health Asp Dev Dis 4 89 93
3. DB Bailey Jr DD Hatton F Tassone M Skinner AK Taylor 2001 Variability in FMRP and early development in males with fragile X syndrome Am J Ment Retard 106 1 16 27 11246709 10.1352/0895-8017(2001)106<0016:VIFAED>2.0.CO;2 (Pubitemid 32181389)
4. DB Bailey Jr M Raspa M Olmsted DB Holiday 2008 Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey Am J Med Genet A 146A 16 2060 2069 18570292 10.1002/ajmg.a.32439 1:CAS:528:DC%2BD1cXhtVCks7vJ
5. E Berry-Kravis SE Krause SS Block S Guter J Wuu S Leurgans, et al. 2006 Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial J Child Adolesc Psychopharmacol 16 5 525 540 17069542 10.1089/cap.2006.16.525 (Pubitemid 44737208)
6. E Berry-Kravis K Potanos 2004 Psychopharmacology in fragile X syndrome-present and future Ment Retard Dev Disabil Res Rev 10 1 42 48 14994287 10.1002/mrdd.20007 (Pubitemid 38375352)
7. KD Burris TF Molski C Xu E Ryan K Tottori T Kikuchi, et al. 2002 Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors J Pharmacol Exp Ther 302 1 381 389 12065741 10.1124/jpet.102.033175 1:CAS:528:DC%2BD38Xlt1SnsLY%3D (Pubitemid 34680462)
8. JN Constantino SA Davis RD Todd MK Schindler MM Gross SL Brophy, et al. 2003 Validation of a brief quantitative measure of autistic traits: comparison of the social responsiveness scale with the autism diagnostic interview-revised J Autism Dev Disord 33 4 427 433 12959421 10.1023/A:1025014929212 (Pubitemid 37127938)
9. CA Erickson KA Stigler D Posey C McDougle 2006 Managing maladaptive behaviors in fragile X patients Curr Psychiatry 5 10 80 92
10. CA Erickson KA Stigler DJ Posey CJ McDougle 2005 Risperidone in pervasive developmental disorders Expert Rev Neurother 5 6 713 719 16274329 10.1586/14737175.5.6.713 1:CAS:528:DC%2BD2MXhtlWmtr%2FJ (Pubitemid 41679639)
11. CA Erickson KA Stigler DJ Posey CJ McDougle 2010 Aripiprazole in autism spectrum disorders and fragile X syndrome Neurotherapeutics 7 3 258 263 20643378 10.1016/j.nurt.2010.04.001 1:CAS:528:DC%2BC3cXhtVOntr3E
12. Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington, DC: U.S. DHEW, NIMH.
13. RJ Hagerman E Berry-Kravis WE Kaufmann MY Ono N Tartaglia A Lachiewicz, et al. 2009 Advances in the treatment of fragile X syndrome Pediatrics 123 1 378 390 19117905 10.1542/peds.2008-0317
14. DD Hatton SR Hooper DB Bailey ML Skinner KM Sullivan A Wheeler 2002 Problem behavior in boys with fragile X syndrome Am J Med Genet 108 2 105 116 11857559 10.1002/ajmg.10216 (Pubitemid 34174313)
15. S Jordan V Koprivica R Chen K Tottori T Kikuchi CA Altar 2002 The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor Eur J Pharmacol 441 3 137 140 12063084 10.1016/S0014-2999(02)01532-7 1:CAS:528:DC%2BD38XksVSiurg%3D (Pubitemid 34626163)
16. C Lord A Pickles J McLennan M Rutter J Bregman S Folstein, et al. 1997 Diagnosing autism: analyses of data from the autism diagnostic interview J Autism Dev Disord 27 5 501 517 9403369 10.1023/A:1025873925661 1:STN:280:DyaK1c%2FmslSksQ%3D%3D (Pubitemid 27513149)
17. RN Marcus R Owen L Kamen G Manos RD McQuade WH Carson, et al. 2009 A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder J Am Acad Child Adolesc Psychiatry 48 11 1110 1119 19797985 10.1097/CHI.0b013e3181b76658
18. JT McCracken J McGough B Shah P Cronin D Hong MG Aman, et al. 2002 Risperidone in children with autism and serious behavioral problems N Engl J Med 347 5 314 321 12151468 10.1056/NEJMoa013171 1:CAS:528:DC%2BD38XlslWqt7Y%3D (Pubitemid 34815353)
19. CJ McDougle JP Holmes DC Carlson GH Pelton DJ Cohen LH Price 1998 A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders Arch Gen Psychiatry 55 7 633 641 9672054 10.1001/archpsyc.55.7.633 1:CAS:528:DyaK1cXkvVagtL4%3D (Pubitemid 28340352)
20. R Owen L Sikich RN Marcus P Corey-Lisle G Manos RD McQuade, et al. 2009 Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder Pediatrics 124 6 1533 1540 19948625 10.1542/peds.2008-3782
21. Roid G, Miller L (1997) Leiter international performance scale-revised. Stoelting Company, Wood Dale (Illinois)
22. L Scahill CJ McDougle SK Williams A Dimitropoulos MG Aman JT McCracken, et al. 2006 Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders J Am Acad Child Adolesc Psychiatry 45 9 1114 1123 16926619 10.1097/01.chi.0000220854.79144.e7 (Pubitemid 44343067)
23. DA Shapiro S Renock E Arrington LA Chiodo LX Liu DR Sibley, et al. 2003 Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 28 8 1400 1411 12784105 10.1038/sj.npp.1300203 1:CAS:528:DC%2BD3sXls1Slsro%3D (Pubitemid 41070874)
24. S Shea A Turgay A Carroll M Schulz H Orlik I Smith, et al. 2004 Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders Pediatrics 114 5 e634 641 15492353 10.1542/peds.2003-0264-F (Pubitemid 41647671)
25. KA Stigler JT Diener AE Kohn L Li CA Erickson DJ Posey, et al. 2009 Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study J Child Adolesc Psychopharmacol 19 3 265 274 19519261 10.1089/cap.2008.093
26. KA Stigler DJ Posey CJ McDougle 2004 Aripiprazole for maladaptive behavior in pervasive developmental disorders J Child Adolesc Psychopharmacol 14 3 455 463 15650503 10.1089/cap.2004.14.455 (Pubitemid 39473132)
27. Wechsler D (1999) Wechsler Intelligence Scale for Children, 3rd edn. Psychological Corporation, San Antonio (Texas)